About me...
H-index: 3 (Scopus)
ORCID: 0000-0002-9538-9180
Striking Achievements
- Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation, Transplantation, 100 (2016), 640-647
- Evaluation of Experiences with Immunosuppressive Drugs in Transplantation: Validation of the MESI Scale in French, Pharmaceutical Medicine, 31 (2017), 455-465
- Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial, Transplantation, 89 (2010), 1255-1262
- Validation of the psychometrics properties of a French quality of life questionnaire among a cohort of renal transplant recipients less than one year, Qul. Life Res., 25 (2016), 2347-2359
- A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation, Pharmacogneomics, 17 (2016), 375-391
- Since 2012: Research engineer at INSERM U850 (Pharmacology of immunosuppressant drugs in transplantation) (University of Limoges – France)
- Since 2005: Clinical research engineer at the Limoges University Hospital (France)
- 2013-2016: PhD at the University of Limoges (Faculty of Sciences) Limoges (France)
- 2000-2005: Production Director at Porcelaines Médard de Noblat (France)
- 1997-2000: Quality Manager at Porcelaines HAVILAND – Limoges (France)
[ul-element-tab-item id="object6499" tabid="object6444" title="Education and Qualification"]
- 2016 PhD Degree
- 1997 Engineer’s degree
- 1995 Master Degree
- 1994 Higher National Diploma in Technology
RESEARCH ACTIVITIES
Since 2012:
- Modelling time-profiles quality of life and adherence over time
- Identification of low quality of life and low adherence determinantsElaboration and validation of patient report outcome dedicated to adherence evaluation
- Elaboration of therapeutic education program dedicated to drugs prescribed to transplant patients with a focus on immunosuppressants
- Involvement in therapeutic education sessions
Since 2005:
- Management of serious adverse events (SAEs)
- Submission of unexpected serious adverse reactions (SUSAR) to the competent authorities
- Coding of medical histories and adverse events with MedDRA dictionary (Medical dictionary for Regulatory Activities)
- Coding of concomitant medication according to ATC Index (Anatomical Therapeutic chemical classification system) published by OMS
- Periodic reconciliations between different databases of clinical trials
- Elaboration of annual safety reports from clinical trials (DSUR: Development Safety Update Report)
- Protocol Review
- Inclusion of information on investigational drugs in XEVMPD (Extended Eudravigilance Medical Product Dictionary)
- Audits of clinical trials
